The biopharmaceutical industry is facing a crisis of inadequate infrastructure for biotechnology research, development and manufacturing.  Existing installations are already operating at maximum capacity, yet all indicators seem to agree that demand for their offerings is only going to increase. 

With the completion of the human genome project and the cultivation of avant-garde drug discovery tools, it is expected that more and more targeted therapeutic proteins will be brought to light.  As they are, they will be caught in a bottleneck, unable to proceed to market through the discovery and development pipeline because the system is too congested.  This will create a backup, delaying or halting the exploration and development of promising territory.

While a shortage of commercial research and development space is not unheralded, a similar dearth of production facilities has caught many companies unaware.  Diversified Bio-Medics addresses this market-imbalance by providing comprehensive, validated facilities and support for cGMP biotechnology manufacturing.

Diversified Bio-Medics, Inc. accompanies the product from its clinical development through to the products market launch:

Diversifed Bio-Medics and the Drug Development Timeline:

The Cost of Drug Development and Diversified Bio-Medics, Inc.

What happens when a potential client approaches Diversified Bio-Medics to manufacture a product once the facility is in full operation.  The following demonstrates what needs to be done in order to complete the process: